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Soon after the introduction of the first antiretroviral
(ARV) agent, zidovudine (AZT), drug-related toxi-
cities became recognized and well-characterized.
Things have since become more complicated;
there are now 17 ARV agents in four distinct class-
es. This has led to both decreased morbidity and
mortality from HIV infection due to immune recon-
stitution and viral suppression, and increasing
recognition of both acute and long-term toxicities
of ARV therapy (ART). Most clinicians agree that
the benefits of ART generally outweigh the risk;
however, patients who experience significant side
effects sometimes disagree with this. This can
lead to patient non-adherence or refusal to take
any ART at all for fear of toxicity. Drug toxicities
may have both acute and long-term implications to
the health of HIV-infected persons. 
This report reviews common acute and long-term
toxicities of ART. Drug toxicities can be class-spe-
cific or ARV-agent specific. Having an under-
standing of these complications allows clinicians
to anticipate potential toxicities, and to communi-
cate about them with their patients. Clinicians
should inform patients considering ART what com-
plications they may experience, how to recognize
these side effects, and what they should do about
them. This proactive approach is likely to lead to a
more trusting relationship and improved adher-
ence.1
Mitochondrial Toxicity
In recent years, mitochondrial toxicity has been
recognized as one of the most serious potential
side effects of ART.2 Mitochondria are the energy-
producing factories of our bodies; when mitochon-
drial production is decreased by inhibition of the
cellular DNA polymerase gamma, end-organ toxi-
city can occur. Mitochondrial toxicity is associated
with the use of the nucleoside and nucleotide
reverse transcriptase inhibitors, and may lead to a
number of clinical problems. These include pan-
creatitis, peripheral neuropathy, and increased
production of lactic acid. 
Pancreatitis
Pancreatitis can be an acute complication of ART,
even though it may occur after years of stable
treatment.3 This potential fatal complication has
been linked predominantly to the use of didano-
sine (ddI); however, stavudine (d4T) and lamivu-
d ne (3TC) have also been associated with pan-
creatitis. There may be an added potential for pan-
creatitis when using combinations of these nucle-
oside reverse transcriptase inhibitors (NRTIs).
Importantly, the concomitant use of alcohol
i creases the risk of pancreatitis. In cases of acute
pancreatitis, temporary interruption of ART is rec-
ommended. Subsequent resumption should avoid
he likely causative agents the patient was taking
t the time he or she developed pancreatitis. 
Peripheral neuropathy
Peripheral neuropathy usually occurs after pro-
longed use of NRTIs.4 This complication is most
often associated with the use of the "d-drugs" -
zalcitabine (ddC), stavudine (d4T), and didano-
sine (ddI) (in decreasing order of likelihood). The
combined use of two of these drugs has been
associated with an even higher incidence of neu-
ropathy. Recognizing neuropathic symptoms early
on, and reducing or interrupting the offending
agent(s) usually leads to symptom resolution. If
patients are maintained on these drugs, progres-
sive and often permanent neuropathy requiring
narcotic analgesia may ensue. 
Lactic acidosis
Lactic acidosis syndrome (LAS) was first reported
in the early 1990s in association with zidovudine
(AZT) use, predominantly in obese African-
American women. In recent years, the greatest
association has been with the use of stavudine
(d4T) with or without didanosine (ddI). The nucle-
oside and nucleotide analogues inhibit mitochon-
drial DNA production, which leads to an increased
breakdown of fatty acids into lactic acid. Inhibition
is greatest for the "d-drugs" but also occurs with
the other NRTIs.5
Patients with LAS generally present with vague
constitutional complaints including fatigue,
malaise, abdominal pain, and nausea and vomit-
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Long-Term Toxicities Associated with HIV and
Antiretroviral Therapy
ing. Over the course of several weeks, these
patients can develop tachypnea, pancreatitis,
and/or hepatitis in the setting of progressive
acidemia. If unrecognized, death may occur.
The clinician considering this diagnosis early
on in the setting of vague complaints should
obtain an arterial or venous lactate level. A
mildly elevated level (2-5 mmol/L) is diagnos-
tic of symptomatic hyperlactatemia, whereas
a level >5 mmol/L in conjunction with a
reduced arterial pH confirms the diagnosis of
LAS. In both situations, interruption of ART
until resolution is necessary. Subsequent
therapy should, when possible, avoid those
drugs most associated with LAS.
Metabolic Complications
Various metabolic complications associated
with HIV have now been recognized. These
include dyslipidemia, insulin resistance/dia-
betes (dysglycemia), and osteopenia/osteo-
porosis. 
Dyslipidemia
Abnormal serum lipids have been noted since
the beginning of the HIV epidemic. In the pre-
ART era, patients commonly had hypocholes-
terolemia and hypertriglyceridemia as a func-
tion of their wasted hypercatabolic state,
combined with increased pro-inflammatory
cytokines.6 However, the highly active ART
(HAART) era has been associated with a dys-
lipidemic profile consisting of high total and
LDL cholesterols, elevated triglycerides, and
a low HDL cholesterol. Although some
patients may exhibit all three of these abnor-
malities, many will only have abnormalities in
either the cholesterol or triglyceride fractions.
The fraction most affected usually depends
on the ARV agent(s) used (for example, riton-
avir (RTV) predominantly affects triglyc-
erides). The effect on lipids is most pro-
nounced with protease inhibitors (PIs), fol-
lowed by non-nucleoside and then nucleoside
reverse transcriptase inhibitors.
The dyslipidemic profile is associated with an
increased risk for atherogenesis, raising con-
cern that as patients live longer due to
HAART they may experience an increased
risk for coronary or cerebral vascular morbid-
ity and mortality.7 Multiple cohort studies com-
paring the frequency of coronary and/or cere-
bral vascular disease in HIV-infected patients
with matched HIV-uninfected controls have
shown an increased incidence of disease in
those with HIV infection. Identification and
management of individuals with dyslipidemia
is now an essential part of HIV care.
Guidelines are now available.8
Dysglycemia
Disorders of glucose metabolism, or dysg-
lycemia, were one of the first metabolic com-
plications of ART identified.9 Initial reports of
new-onset hyperglycemia, including episodes
of diabetic ketoacidosis, were linked to the
use of protease inhibitors (PIs). Subsequent
cohort studies have confirmed this associa-
tion, which is largely due to acquired insulin
resistance.10 Patients with HCV co-infection
appear to be at greater risk of developing this
complication. 
Diagnosis is usually performed through peri-
odic fasting glucose determinations or by a
two-hour oral glucose tolerance test.
Glycosylated hemoglobin levels are usually
normal even in the setting of insulin resis-
tance. Treatment depends on the severity of
the hyperglycemia, with mild cases respond-
ing to dietary intervention and exercise, mod-
erate cases responding to insulin-sensitizing
agents such as the glitazones, and severe
cases responding to insulin therapy.
Modifying the regimen by replacing the PI
with a non-PI agent may also be successful.
Disorders of Bone
Metabolism
More recently, disorders of bone metabolism
have been recognized as another long-term
complication seen in HIV-infected patients.11
Osteopenia and osteoporosis have both been
described in patients on ART, but predomi-
nately in those on HAART. The etiology of
these changes has not been delineated,
although there is a suggestion that the HIV-1
protease inhibitors may contribute to this
process by affecting osteoclast or osteoblast
differentiation. Diagnosis is made by standard
DEXA scanning, although at this time routine
DEXA scanning of all HIV patients is not indi-
cated. However, for those with other risk fac-
tors for osteoporosis, such as family history,
hypogonadism, smoking, and corticosteroid
use, screening DEXA scanning should be
considered. Preliminary studies have shown
that alendronate is effective at treating osteo-
porosis in these patients.
Lipodystrophy
One of the most disconcerting toxicities
increasingly recognized in the past three
years is lipodystrophy, a disturbance in the
way the body produces, uses, and distributes
fat.12 Patients with long-term HIV infection,
especially those treated with antiretroviral
therapy, may exhibit changes in body mor-
phology due to changes in fat distribution.
Although these changes are usually not asso-
ciated with medical complications, the disfig-
urement can be psychologically disabling.
Various cohort studies have estimated that up
to 50% of patients suffer from lipodystrophy.
Two patterns have emerged. Lipoatrophy, or
subcutaneous fat loss, is seen most com-
monly in the face, extremities, and buttocks.
Lipohypertrophy, or increased fat deposition,
is seen predominantly in the abdominal
region ("paunch"), dorsocervical region ("buf-
falo hump"), and breasts. Patients often have
a combination of the two types of dysmorphic
features.
The pathogenesis of fat maldistribution
remains elusive. Retrospective cohort studies
have defined characteristics associated with
development of lipodystrophy: these include
an age >40 years, nadir CD4 cell count,
Caucasian race, and antiretroviral use. More
recently, a prospective study of ARV-naïve
patients initiating therapy showed an associa-
tion between development of lipoatrophy and
use of a stavudine-containing regimen, and
lipohypertrophy and the use of a PI-contain-
ing regimen. These investigators also defined
a pattern to changes in body morphology
occurring after initiation of therapy.
Specifically, patients gained fat and lean
mass during the first 24 weeks of therapy, fol-
lowed by progressive loss of extremity fat
while preserving gained central abdominal fat
over the next 72 weeks of therapy.13
No definitive treatment for fat maldistribution
exists, though different approaches have
been tried. For lipoatrophy, several studies
have shown that substitution of either zidovu-
dine (AZT) or abacavir (ABC) for stavudine
(d4T) may be associated with increases
(albeit small) in subcutaneous fat, compared
to continued declines in those remaining on
stavudine (d4T). For lipohypertrophy, replace-
ment of the protease inhibitor with a reverse
transcriptase inhibitor may be useful.14
Cosmetic surgical options to treat facial lipoa-
t ophy include a variety of methods of soft tis-
sue augmentation. Although none of these
procedures are specifically FDA-approved for
this indication, some are FDA permissible as
off-label use of approved agents. Bio-
absorbale materials used for soft tissue aug-
mentation include Zyplast collagen, human
cadaveric dermal tissue (Cymetra), or fascia
lata (Fascian) polylactic acid (Newfill),
hyaluronic acid (Perlane) and fat transfers.
Permanent options include implants, liquid
injectable medical grade silicone (Silikon-
1000), and polymethylmethacrylate (Artecoll).
For buffalo humps that cause disfigurement,
neck pain, or sleep apnea, liposuction may be
effective. Human growth hormone has also
been shown to decrease buffalo hump and
excess abdominal fat.15 However, high cost
a d tolerability issues have led few patients to
use this approach. Once ongoing research
establishes the definitive cause of fat maldis-
tribution, more specific therapeutic options
can be developed.
Hepatotoxicity Unrelated
to Chronic Viral
Hepatitis
Previous articles in HEPP Report have exten-
sively covered the effects of chronic HBV and
HCV in patients with HIV (go to www.hivcor-
rections.org). However, hepatotoxicity occurs
in HIV-infected patients even in the absence
of chronic viral hepatitis. Some of these are
acute drug toxicities, such as those seen with
2
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Dear Correctional Colleagues:
In this month's main article, Dr. Peter Piliero discusses mitochondrial toxicity, which is
responsible for many of the long-term complications of antiretroviral therapy. These com li-
cations, along with the development of viral resistance, are the primary reasons for
delaying the initiation of antiretroviral therapy in HIV-infected patients. This delay provides
the opportunity and time to establish an effective provider-patient relationship and to edu-
cate patients about the risks and benefits of antiretroviral therapy. Such an approach will
lead to improved acceptance of and adherence to antiretroviral therapy, as well as earlier
recognition of complications that can be addressed by appropriate changes in antiretroviral
therapy. 
In this month's spotlight, Drs. Bhupinder Mann and Joseph Bick describe the sudden
appearance of SARS and its effect on an unprepared public and health care system.
Although fear may be the first response to life-threatening emerging infectious diseases,
rational plans of response that are informed by facts are the only ways to respond to and
contain emerging pathogens.  It is unclear what the magnitude of the SARS problem will be
in the United States. But it is clear that all heath care facilities, including prisons and jails,
should develop a plan to contain and treat this infection if and when it appears at our
doorsteps. 
After reading this issue, you should be familiar with toxicities associated with antiretroviral
therapies, including common toxicities across drug classes and with specific agents. You
should also be familiar with issues relating to the SARS virus, including how it is transmit-
ted, symptoms, making a diagnosis, and what to think about when implementing a plan in a
correctional facility. 
As always, please contact us with your suggestions and comments. 
Sincerely yours, 
David Paar 
Letter from the Editor
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Editor's note:Bhupinder Mann, M.D., is a Mayo Clinic-trained hema-
tologist/oncologist who spent several years working in correctional
health at the California Medical Facility in Vacaville, CA. Dr. Mann is
currently a Senior Consultant in Medical Oncology at the National
Cancer Centre of Singapore, and has firsthand experience with the
SARS epidemic.
The sudden global emergence of Severe Acute Respiratory Syndrome
(SARS) has sickened over 8,000 individuals, crippled health care
delivery, and has had a devastating impact on the economy. The
causative agent, a novel Coronavirus, is not previously known to
cause disease in humans. Thus far, no specific treatment, vaccination
or reliable and readily available diagnostic tests are available. Exactly
where we are in the course of this epidemic is not yet clear. 
Transmission
Most infections have been acquired by close contact with a sympto-
matic individual. The virus has been cultured from nasopharyngeal
secretions and stool, and has been shown to remain viable for sever-
al hours outside the body on plastic and other surfaces. It appears that
respiratory droplets are the primary source of transmission. However,
large clusters have been documented to result from nebulizer-gener-
ated aerosols and fecal-oral transmission (traced to damaged sewage
system in an apartment complex).
Symptoms
The incubation period ranges from two to 16 days; the average is six
days. Common symptoms include fever (100%), chills, rigors, myal-
gias, cough (>50%) and sputum, sore throat, coryza, nausea, vomit-
ing, diarrhea (20-30%). Seventy percent of patients have moderate
lymphopenia, and 45% have mild thrombocytopenia.
At the time of initial presentation, 70-80% of patients demonstrate
varying patterns of air-space consolidation on CXR. Hypoxemia requir-
ing ICU care develops in 20-30% of cases. The mortality rate appears
to be dependent upon age, with an overall death rate of 14-15% and
as high as 55% in those over 60 years of age. 
Diagnosis
The initial diagnosis of SARS relies on suspicion based on a patient's
history. Specifically asking patients about their history of travel to
affected areas, visits to an affected health care facility, or history of
casual social contact with a suspected or probable case is critical.
Relying on initial symptoms alone, it is hard to differentiate SARS from
any other flu-like illness. Since a reliable, rapid diagnostic test is not
presently available, clinicians must rely on symptoms, signs, and
exposure/travel history. Many patients develop an ARDS-like clinical
picture. Suspect cases should receive a chest x-ray, pulse oximetry,
and blood cultures. Gram stain of sputum and testing for other respi-
ratory viruses such as influenza should be performed.
RT-PCR can rapidly document the presence of coronavirus RNA.
Antibody response is now known to develop over time in serum; how-
ever, the sensitivity and specificity of these tests has not yet been
established. Specimens from suspect cases should be saved for fur-
ther testing, and acute and convalescent serum samples should be
obtained from individuals who meet the SARS case definition (see
Table 1). 
Infection Control
Appropriate precautions need to be taken while evaluating suspected
patients, starting from the point of triage. Patients with suspicious
symptoms should be provided with a surgical mask upon arrival. When
possible, suspect cases should be evaluated in a designated area.
Control of the epidemic relies on quarantining exposed individuals and
tracing their contacts. Institutionalized individuals who may have been
exposed, and their caretakers, should have their temperature checked
regularly.
Clinicians and others who work in health care settings need to adhere
to strict respiratory and contact precautions. All individuals should
undergo mask fit testing. Staff need to learn the proper methods for
putting on, removing, and disposing of personal protection gear. Those
evaluating suspect cases should use standard precautions (hand
washing), airborne precautions (N-95 respirator), and contact precau-
tions (gowns and gloves). Hospital disinfectants including those based
o  quaternary ammonium, phenol and alcohol, are highly active
against coronaviruses.
During an outbreak, patients and caretakers should remain separated
from others in order to minimize the chance of spread to other patients
and health care workers. Also, the number of social visitors into the
facility needs to be restricted, elective procedures should be delayed,
and the number of staff caring for SARS patients should be limited.
SARS in the United States
In the United States SARS has occurred in people with a history of
travel to countries with SARS. In the U.S., casual contact with SARS
patients has not resulted in transmission of the causative virus. Efforts
to prevent SARS in this country have focused primarily on screening
for illness in those arriving from areas with high rates of SARS. At this
tim , the Centers for Disease Control and Prevention (CDC) does not
recommend quarantine of persons arriving from areas with SARS. 
Correctional Facilities
Currently, those of us working in correctional facilities might feel some-
what protected from the SARS epidemic. However, many believe that
this virus will continue to circulate, and that the number of cases
(including those in the U.S.) will increase. Respiratory viruses such as
influenza tend to wane in the warmer months and return with the cold-
er weather. The Directors of the National Institutes of Allergy and
Infectious Diseases (NIAID) and the CDC have stated that they believe
that SARS will persist and amplify in the years to come. 
A Correctional Perspective on Severe Acute Respiratory Syndrome (SARS)
Bhupinder Mann*, M.D. and Joseph Bick*, M.D.
TABLE 1: SARS Case Definition
Severe respiratory illness 
w Temperature of >100.4º F (>38º C), and 
w One or more clinical findings of respiratory illness (e.g., cough,
shortness of breath, difficulty breathing, or hypoxia), and 
w radiographic evidence of pneumonia, or 
w respiratory distress syndrome, or 
w autopsy findings consistent with pneumonia or respiratory 
distress syndrome without an identifiable cause. 
AND 
Epidemiological criteria
w Travel (including transit in an airport) within 10 days of onset of
symptoms to an area with current or previously documented or
suspected community transmission of SARS, or 
w Close contact* within 10 days of onset of symptoms with a per-
son known or suspected to have SARS
* Close contact is defined as having cared for or lived with a per-
son known to have SARS or having a high likelihood of direct con-
tact with respiratory secretions and/or body fluids of a patient
known to have SARS. Examples of close contact include kissing
or embracing, sharing eating or drinking utensils, close conversa-
tion (<3 feet), physical examination, and any other direct physical
contact between persons. Close contact does not include activi-
ties such as walking by a person or sitting across a waiting room
or office for a brief period of time.
Continued on page 5
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If this scenario unfolds, management of patients presenting with what
appears to be a routine viral syndrome or community-acquired pneu-
monia will become much more problematic. Even now, the staff and
visitors of correctional facilities are a potential source for the introduc-
tion of SARS into a jail or prison. One can easily imagine how rapidly
this illness might overwhelm a vulnerable population crowded togeth-
er in a congregate living environment. 
Implementing a Plan
The worldwide experience with SARS has allowed us to strategize for
the likely eventuality of SARS in our practice settings. The following
questions should be kept in mind while preparing a plan to manage
SARS in the correctional setting.
w Can you obtain enough masks for all patients and staff who may
need them? 
w Do you have the ability to do fit testing? 
w Can you isolate (or at a minimum cohort) all suspect cases? 
w Is custodial staff prepared to control inmate movement? 
w Do you have adequate contracts with outside agencies to provide
appropriate medical services? 
w Will you be able to feed inmates and continue other necessary pro-
grams in the event of controlled movement? 
w Do you have enough health care staff to ensure the provision of
necessary services in the event of an outbreak?
*Disclosures: Nothing to disclose.
AGENT POSSIBLE CLASS TOXICITIES ADDITIONAL TOXICITIES
NRTI
Abacavir (ABC; Ziagen)
Didanosine (ddI; Videx)
Lamivudine (3TC; Epivir)
Stavudine (d4T; Zerit)
Zalcitabine (ddC; Hivid)
Zidovudine (AZT;
Retrovir)
NtRTI
Tenofovir (TDF; Viread)
NNRTI
Delavirdine (DLV;
Rescriptor)
Efavirenz (EFV; Sustiva)
Nevirapine (NVP;
Viramune)
PI
Amprenavir (APV;
Agenerase)
Indinavir (IDV; Crixivan)
Nelfinavir (NFV; Viracept)
Ritonavir (RTV; Norvir)
Saquinavir (SQV; 
Invirase, Fortovase)
Lopinavir/Ritonavir
(LPV/RTV; Kaletra)
Hypersensitivity reaction
Pancreatitis, peripheral neu-
ropathy
Pancreatitis
Peripheral neuropathy, pan-
creatitis, hepatoxicity
Pancreatitis, peripheral neu-
ropathy, oral apthae
Anemia, leukopenia, neu-
tropenia, myositis
Lactic acidosis
Hyperlipidemia
Hepatitis
Hepatitis
Mitochondrial toxicity (pancreatitis, peripheral neuropath ,
lactic acidosis) and lipodystrophy
Mitochondrial toxicity (pancreatitis, peripheral neuropathy,
lactic acidosis) and lipodystrophy
Mitochondrial toxicity (pancreatitis, peripheral neuropathy,
lactic acidosis) and lipodystrophy
Mitochondrial toxicity (pancreatitis, peripheral neuropathy,
lactic acidosis) and lipodystrophy
Mitochondrial toxicity (pancreatitis, peripheral neuropathy,
lactic acidosis) and lipodystrophy
Mitochondrial toxicity (pancreatitis, peripheral neuropathy,
lactic acidosis) and lipodystrophy
Hepatotoxicity; potential to cause rash
Hepatotoxicity; potential to cause rash
Hepatotoxicity; potential to cause rash
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Hyperglycemia, hyperlipidemia, and  lipodystrophy.
Increased risk for osteopenia and osteoporosis.
Adapted from Bartlett, et al. 2001-2002 Medical Management of HIV Infection; and Sande, et al. The Sanford Guide to HIV/AIDS Therapy,
2002, Eleventh Edition.
Common Toxicities Among ARVs
SARs... (continued from page 4)
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DISCUSSION: It was fortunate for this woman that the alert infirmary
provider did not send her back to her room to wait a little longer for
the "flu" to resolve. The provider in this case promptly checked a bat-
tery of laboratory tests. The patient's urinary analysis was leukocyte
esterase trace-positive and positive for ketones. Serum AST (92
units), ALT (118 units), total bilirubin 1.7 (units), and amylase normal.
BUN/creatinine were 27/1.6 units, and electrolytes were Na 139
units, Cl 104, K 4.3, and HCO3 12.; The anion gap (AG) was com-
puted as follows: 
AG = (Na + K) - (Cl + HCO3) or AG = Na - (Cl + HCO3)
AG normal value < +/- 12mEq/L
or < 16 mEq/L if potassium concentration is used to calculate value
The result is 23. The correct diagnosis for this woman's illness is gap
acidemia.
The medical provider held the patient's medications and sent her to the
hospital for further evaluation and treatment. 
In the hospital, the medical team obtained a serum venous lactic acid
level, following the ACTG Guidelines Protocol (http://aactg.s-
3.com/members/psmet.htm). The reading was 6.1 mmol/L (normal is
0.5 to 2.5 mmol/L at this institution). An ultrasound of her abdomen
revealed hepatomegaly with fatty infiltration. A diagnosis of severe
nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic
acidemia with hepatic steatosis was confirmed and the patient's anti-
retroviral medications were discontinued. 
What is the most likely cause of anion gap acidosis in this
patient?
An acidosis can be caused by several things. Medication-induced
renal tubular acidosis and chronic diarrhea can cause an acidosis, but
not a gap acidosis, as seen here. Sepsis can cause lactic with an
anion gap, but this patient did not appear to have sepsis clinically. This
patient's gap acidosis was caused by medication-induced lactic acad-
emia.
Lactic academia and mitochondrial toxicity in HIV infection
The mitochondria are the body's battery packs, producing and storing
adenosine triphosphate (ATP) through a (non-lactate-producing)
process of cellular respiration and breaking it down when energy is
required. The number of mitochondria in cells of any particular tissue
varies, depending on tissue energy requirements. Cells of relatively
quiescent tissue may contain only a few mitochondria; the cells of tis-
sues with higher energy requirements - such as muscle, liver, and
nerves - may contain thousands of mitochondria. Mitochondria have
their own DNA strands (mtDNA) that are replicated by the enzyme
polymerase gamma (pol gamma). Pol gamma is very similar to the HIV
polymerase reverse transcriptase. 
NRTIs that inhibit HIV reverse transcriptase may also interfere with
polymerase gamma, apparently causing mutations in the replicating
mitochondria. Mitochondria do not have a mechanism for correcting
replication mutations caused by the NRTIs. As the number of non-
functioning mitochondria increases, the cell loses some of its ability to
produce energy from the non-lactate-producing respiration process. A
"back-up" (lactate-producing) anaerobic energy production system is
activated. Lactate, which is a by-product of anaerobic respiration, is
released from the cell into surrounding tissues and the bloodstream,
where in healthy persons, it is cleared mainly by the liver. The anaer-
obic process is not intended by nature to be the cell's primary energy
source; rather, it is for times when extra energy is required - during
exercise, for example. A person with compromised mitochondria
seems to be using this reserve system for daily energy and may not be
not clearing lactic acid sufficiently. Thus, NRTIs can precipitate abnor-
malities, dysfunction, then toxicity, especially in someone with liver
damage.
Mitochondrial dysfunction leads to varied pathology and is not easy to
predict. HIV disease alone can cause a variety of abnormalities. This
is a list of selected in vivomanifestations of NRTI-associated mito-
chondrial toxicity:
w Neuromuscular - Myopathy: zidovudine (AZT); Polyneurophathy:
zalcitabine (ddC), didanosine (ddI), stavudine (d4T)
w Hepatic/GI - Steatosis, lactic acidosis: zidovudine (AZT) didanosine
(ddI), stavudine (d4T), zalcitabine (ddC); Pancreatitis: didanosine
(ddI), stavudine (d4T)
w Hematologic - Pancytopenias: zidovudine (AZT)
w Nephrologic - Proximal renal tubular dysfunction: adefovir
(Hepsera)
w Metabolic - Lipodystrophy (new theory): stavudine (d4T)
Why are so many different tissues affected?
Some thoughts are that 1) each tissue may have different NRTI kinet-
ics (tissue levels of drugs may differ); 2) each tissue may have differ-
ent activation enzymes (levels of active drug may differ); 3) each tis-
sue may have different underlying proportion of mutant mtDNA; 4) it is
known that NRTIs vary in their ability to inhibit mtDNA polymerase; 5)
the role of mitochondria may be more or less important in certain tis-
sues.
The Food and Drug Administration (FDA) reported 106 cases of lactic
acidemia through June 1998. There were 46 cases associated with the
use of a single NRTI (mainly AZT) and 61 cases associated with a
combination of NRTIs including d4T, ddI, or AZT. In 69% of these
cases, hepatic steatosis was present. There were 20 fatalities (85%
female; 65% females obese). The French reported 11 cases in 867
(0.84%) patients over 18 months: d4T/ddI (n=7); d4T/3TC (n=2); d4T
(n=2). Hepatic steatosis was present in four of five biopsies. There was
one fatality. Four of the patients had HCV co-infection. They report
treating lactic acidemia with riboflavin and carnitine.
Treating Mitochondrial Toxicities
Effective treatments still need to be evaluated. Current theories of
Case presentation and discussion by Stephen Tabet, MD, MPH, Assistant Professor of Medicine, University of Washington, and Director, Northwest
Correctional Medicine Education Program. A collaboration with the Northwest AIDS Education and Training Center, with Stephen Tabet, MD, and Kate
Willner, trainer.
Ask the Expert
Case Study: 38-year-old Woman With Persistent Flu-like Symptoms
(Continued on page 7)
CASE: A 38-year-old woman presents to the prison infirmary with flu-like complaints consisting of myalgias, abdominal pain, and nausea. Her
medical history is significant for Class A2 HIV disease. She has had no HIV-related illnesses except for chronic, mild diarrhea. Her CD4 T-cell
count is 512 (32%), and HIV RNA by bDNA is less than 50. Her antiretroviral regimen consists of stavudine (d4T), lamivudine (3TC), and indi-
navir/ritonavir (IDV/RTV). Her only other illness is asymptomatic chronic hepatitis C virus (HCV) infection. She first reported to the infirmary
one week ago, complaining of one week of flu-like illness. Total time since onset is two weeks. On examination today, the patient appears
moderately ill. Her blood pressure is 112/64, pulse 105, respirations 22, and temperature 37.1 C. Her right upper abdomen is tender to palpa-
tion. Because there has been no improvement in her symptoms, her medical care provider decides that further investigation is warranted.
If this were your patient, what would you be concerned about right now, and how would you proceed to make the diagnosis?
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hypersensitivity to nevirapine (NVP). One under-recognized toxicity is
non-alcoholic steatohepatitis (NASH). NASH may be seen in HIV-unin-
fected patients and is usually associated with obesity, diabetes, or cer-
tain medications, and can progress to cirrhosis if untreated. In HIV-
infected patients, NASH has been reported to occur in those with pro-
longed hypertriglyceridemia and insulin resistance, usually secondary
to HAART. These patients present with sustained, mild-to-moderate
elevations in serum transaminases (AST or ALT) with no serologic or
virologic evidence of chronic HBV or HCV infection. Hepatic ultrasound
or CT scan will show a pattern consistent with fatty liver. Liver biopsy
will show steatosis with or without fibrosis or cirrhosis. Treatment
involves therapy for the hypertriglyceridemia or insulin resistance,
abstinence from any alcohol intake, use of antioxidants such as vita-
mins C and E, and in some cases alteration of the current ARV thera-
py to remove the agents contributing to hypertriglyceridemia or insulin
resistance.16
Conclusion
The ART era has been a miraculous time for many patients with HIV
infection and for those providing care. For patients with access to ARV
therapy, HIV/AIDS has the potential to become a manageable, chron-
ic disease. However, there are many prices to pay for this, including a
lifetime need for complex medical regimens associated with acute tox-
icities. In the last few years, we have learned that there are chronic
complications of both ARV therapy and prolonged survival with HIV
infection. Some of these complications can be immediately life-threat-
ening, whereas others have implications for patients' future morbidity
and mortality. In either case, patients and health care providers must
recognize that these long-term complications exist. Importantly, health
care providers need to understand how to diagnose and manage these
complications in order to provide optimal long-term care to their
patients with HIV infection.
*DISCLOSURES: Abbott (honoraria, consultant); Roche, Merck,
GlaxoSmithKline, BMS (honoraria, research funding)
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treatment focus on assisting the respiratory chain function with 1)
Coenzyme Q - electron transfer with complex* III (portions of the ATP
electron transport chain in the mitochondria), 2) riboflavin - a cofactor
for electron transport complexes I and II, or 3) L-carnitine, a shuttle
mechanism for fatty acid transport across the mitochondria. These
have shown varying efficacy in uncontrolled trials to date. Challenges
in studying mitochondrial toxicity (MT) include the lack of cell line or
animal model to reliably predict MT. In vitromodels may provide impor-
tant information but experience with fialuridine (FIAU) and recently
with lodenosine (FddA) shows that clinical experience is the most reli-
able indictor. 
Hepatic Steatosis
Hepatic steatosis is a frequent finding at biopsy, most often attributed
to alcohol, obesity, diabetes, or drugs. If fatty acid oxidation in hepatic
mitochondria is impaired, triglycerides may accumulate as small lipid
vesicles in hepatocytes. Acute microvesicular steatosis can be very
serious, leading to liver failure and death. 
Resuming antiretroviral therapy
This patient improved after two days in the medicine intensive care
unit, and an additional four days in the acute care ward. She returned
to the facility and was seen in the infirmary for follow up. At one month,
her labs were rechecked and results showed Na 137, Cl 106, and CO2
21. At two months, post-discharge her electrolytes were normal, and
she was no longer acidemic. However, the patient's HIV RNA
increased to 16,000 units (it had been undetectable) and her CD4
count was 392 units (down from 512 units). The patient was hesitant
to restart antiretroviral therapy, and since her viral load and CD4 are at
acceptable levels for now, the bottom line for this patient is "wait and
see." When she does require therapy, NRTIs previously used in her
treatment regimen will not be used and an NRT-sparing regimen will
be considered.
Summary
If lactic acidemia is not specifically looked for, it may not be diagnosed
in time. The disease varies in presentation, and its common symptoms
- nausea, vomiting, fatigue, myopathy, abdominal pain, and recent
weight loss - are also symptomatic of HIV disease itself. There are cur-
rently limited diagnostic tests for toxicity and a serum specimen to
measure for lactic acid must be drawn carefully according to protocol.
Reference
AACTG Metabolic Guidelines for Hyperlactatemia and Lactic
Acidosis, http://aactg.s-3.com/metabolic/lactic.pdf
For a list of references please email Kate Willner at
kwillner@u.washington.edu
Ask the Expert... (continued from page 6)
Legal Issues in Correctional
Health Care
Sponsored by NCCHC and the
American Bar Association Criminal
Justice Section
June 27-28, 2003
Chicago, Illinois
Call: 773-880-1460
Visit: www.ncchc.org/
edu_legal2003/legal_conf.pdf
American Correctional
Association Summer
Conference
August 9-13, 2003
Nashville, Tennessee
Call: 800-222-5646, ext. 1922
Visit: www.aca.org/conventions/
conventions_2003_summer.htm
3rd Annual Intensive Review in
Correctional Medicine
Sponsored by the Correctional
Medicine Institute (CMI), 
the Society for Correctional
Physicians (SCP), and 
Johns Hopkins University
September 4-6, 2003
Baltimore, Maryland
Baltimore Marriott Waterfront Hotel
Call: 314-607-1565
Email: admin@cm-institute.org
Visit: www.cm-institute.org
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The United States Conference
on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
HIV Minifellowship for
Correctional Health Care
Providers
Sponsored by the University of
Texas Medical Branch 
and HEPP Report, 
Brown University
September 22-24, 2003
Providence, Rhode Island
Call: 409-747-8769
Email: pwelsh@utmb.edu
Save the 
Dates
8
Save the Date: "Texas" Minifellowship
The annual HIV Minifellowship for Correctional
Health Care Providers will be held in Providence,
Rhode Island, on September 22, 23, and 24,
2003. Sponsored by the University of Texas
Medical Branch and HEPP Report, the confer-
ence will feature discussions by leading correc-
tional care providers and infectious disease spe-
cialists. Topics will include HIV epidemiology,
opportunistic infections, HIV/HCV co-infection,
mental health issues, guidelines for initiating and
modifying ARV, and ethical issues. Call 409-747-
8769 or email pwelsh@utmb.edu to register.
Number of Syphilis Cases in NJ Triples
The number of New Jersey men diagnosed with
syphilis has more than tripled in the last three
years, and the rise in numbers could be due to
increased risky behavior, ultimately leading to
more HIV infections, according to the Bergen
Record. The number of syphilis cases decreased
throughout the 1990s but has spiked since 2000.
New Jersey Health Department officials report
that 121 men (mostly men who have sex with
men) and 48 women were diagnosed with
syphilis in 2002. Bergen Record, 5/4/03
Many Minorities With HIV Not Taking HAART
An analysis of 200 HIV-infected patients who
died at a Texas hospital in between 1995 and
2000 found that more than half of them were not
taking HAART. Despite the availability of HAART,
only 48% of patients who died in 1999-2000 were
taking HAART at the time of death, according to
the authors. The main reasons the patients were
not taking the drugs were an inability to adhere to
the regimen, an HIV diagnosis less than six
months prior to death, or an inability to tolerate
the drugs due to underlying liver disease. The
study also found that many of the HIV-infected
individuals who were not receiving HAART were
minorities. Journal of Clinical Infectious
Diseases, 2003;36(8):1030-1038
Study: How Often Should Liver Biopsy Be
Performed?
A study in the Journal of Hepatology found that
an interval of at least four to five years is needed
between liver biopsies to detect significant
changes in patients with mild liver disease. One
hundred and eighty patients with histologically
proven chronic hepatitis C were studied. The
authors concluded that fibrosis progression is
very slow in patients with mild chronic hepatitis C,
but that it appears to be accelerated in the later
stages of disease. Increasing age and daily alco-
hol consumption are the main factors associated
with significant fibrosis. Journal of Hepatology,
2003;38(3):307-314
Study: Methadone and Pegasys Interactions
and Safety
Researchers from Johns Hopkins University pre-
sented results at the Digestive Disease Week
(DDW) 2003 conference of a four-week study
evaluating interactions between methadone and
Pegasys. Methadone exposure increased by
10%-15% during the first four weeks of taking
both medications together, but the study found
that methadone did not have an impact on the
pharmacokinetics or pharmacodynamics of
Pegagys. The authors concluded that dose mod-
ifications of Pegasys are not required and the
combination of the drugs is safe and well tolerat-
ed. NATAP (www.natap.org), 5/20/03
Man Has HIV Superinfection
A man has been infected with two different strains
of HIV, researchers report in the May 2, 2003 edi-
tion of AIDS. Although the immunological
response to HIV-1 infection is believed to impede
"superinfection" with a second virus, study
authors report that this is not always the case.
About four months after infection with drug-resis-
tant clade B virus, the patient was infected by a
second drug-sensitive wild-type virus from the
same subtype. His viral load then jumped from
34,000 copies/mL to almost 200,000 copies/mL.
AIDS 2003; 17:F11-F16 and Reuters, 5/19/03
Study: Evaluation of 24-Hour Viral Response
to HCV Combination Therapy
At the DDW 2003 conference in Florida,
researchers from the University of Vienna pre-
sented results of a prospective evaluation of 24-
hour viral response in predicting outcome of treat-
ment with Pegasys and ribavirin. While the 12 or
24 week response is more accurate at predicting
ETR and SVR, the authors concluded that the 24-
hour viral response rate is a sensitive predictor of
the response to therapy, and may be useful in
certain situations. 
NATAP (www.natap.org), 5/21/03
Inside News
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Resources
New OHRP Guidance on the Involvement of
Prisoners in Research
http://ohrp.osophs.dhhs.gov/humansubjects/guid-
ance/prisoner.htm
The Office for Human Research Protections
(OHRP) on May 23,2003 posted a new guidance
document on the OHRP website: "OHRP
Guidance on the Involvement of Prisoners in
Research." The new document replaces the pris-
oner research guidance document titled "OPRR
Guidance on Approving Research Involving
Prisoners" from May 19, 2000. 
SARS Resources
w Centers for Disease Control and Prevention:
www.cdc.gov/ncidod/sars/
w World Health Organization:
www.who.int/csr/sars/en/
w New England Journal of Medicine:(SARS
content is posted free for all visitors) 
http://content.nejm.org/early_release/sars.dtl
w CDC Public Health Training Network
Satellite Broadcast & Webcast:Includes
archived webcast and presenters' slides.
www.phppo.cdc.gov/PHTN/webcast/sarsII/
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Mitochondrial toxicity has been primarily associated with:
(a) PIs
(b) NRTIs
(c) NNRTIs
(d) NRTIs and NNRTIs
2. Mitochondrial toxicity can lead to:
(a) Pancreatitis, peripheral neuropathy, and lactic acidosis
(b) Pancreatitis, dyslipidemia, and hepatitis
(c) Lactic acidosis, dyslipidemia, and pancreatitis
(d) Lipodystrophy, peripheral neuropathy, and lactic acidosis
3. Cohort studies have estimated that up to 70% of patients suf-
fer from lipodystrophy.
(a) True
(b) False
4. HIV-infected patients with non-alcoholic steatohepatitis
(NASH) can present with sustained, mild-to-moderate AST or
ALT elevations, even in the absence of serologic evidence of
chronic HBV or HCV.
(a) True
(b) False
5. Preliminary studies have shown that the following medication
might be effective for the treatment of HIV-infected patients with
osteoporosis:
(a) Calcitonin
(b) Alendronate
(c) Raloxifene
(d) Calcium supplements
6. The dyslipidemic profile includes the following except:
(a) High LDL cholesterol
(b) Elevated triglycerides
(c) Pancreatitis
(d) Low HDL cholesterol
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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